People often think of leprosy as a bygone disease, relevant primarily in biblical times. But in fact, it is still present in more than 120 countries, and the US is seeing an uptick in cases.
Category: biotech/medical – Page 706
‘Dramatic’ inroads against aggressive brain cancer
A collaborative project to bring the promise of cell therapy to patients with a deadly form of brain cancer has shown dramatic results among the first patients to receive the novel treatment.
In a paper published Wednesday in The New England Journal of Medicine, researchers from Mass General Cancer…
Cutting-edge therapy shrinks tumors in early glioblastoma trial.
Transgenic cows boost human insulin production by 10X
A genetically modified cow has produced milk containing human insulin, according to a new study. The proof-of-concept achievement could be scaled up to, eventually, produce enough insulin to ensure availability and reduced cost for all diabetics requiring the life-maintaining drug.
Unable to rely on their own supply due to damaged pancreatic cells, type 1 diabetics need injectable insulin to live. As do some type 2 diabetics. The World Health Organization estimates that of those who require insulin, between 150 and 200 million people worldwide, only about half are being treated with it. Access to insulin remains inadequate in many low-and middle-income countries – and some high-income countries – and its cost and unavailability have been well-documented.
In a newly published study led by the Department of Animal Sciences in the College of Agricultural, Consumer and Environmental Sciences at the University of Illinois Urbana-Champaign and the Universidade de São Paulo, researchers say they may have developed a way of eliminating insulin scarcity and reducing its cost using cows. Yep, cows.
Revolutionary Graphene Interfaces Set to Transform Neuroscience
Groundbreaking graphene neurotechnology developed by ICN2 and collaborators promises transformative advances in neuroscience and medical applications, demonstrating high-precision neural interfaces and targeted nerve modulation.
A study published in Nature Nanotechnology presents an innovative graphene-based neurotechnology with the potential for a transformative impact in neuroscience and medical applications. This research, spearheaded by the Catalan Institute of Nanoscience and Nanotechnology (ICN2) together with the Universitat Autònoma de Barcelona (UAB) and other national and international partners, is currently being developed for therapeutic applications through the spin-off INBRAIN Neuroelectronics.
Key Features of Graphene Technology.
APOE from patient-derived astrocytic extracellular vesicles alleviates neuromyelitis optica spectrum disorder in a mouse model
Analyzing cells from patients with neuromyelitis optica spectrum disorder, researchers show transfers of patient-derived extracellular vesicles rich in the apolipoprotein APOE alleviate neuroinflammation and slow astrocyte loss in a mouse model of this severe autoimmune disease.
📄 :
APOE was augmented in astrocytic extracellular vesicles from patients with neuromyelitis optica spectrum disorder and decreased brain lesions in a mouse model.
Dr. William Kapp, MD — CEO, Fountain Life — Preventative, Predictive, Personalized Healthcare
Preventative, predictive and personalized healthcare and longevity — dr. william kapp, MD — CEO, fountain life.
Dr. William Kapp, MD is Chief Executive Officer of Fountain Life (https://fountainlife.com/about/), a company focused on transforming the current healthcare system into one that is both proactive and data-driven, enabling enhanced longevity and catching and treating illnesses earlier than ever before, focusing on the detection and reversal of asymptomatic diseases and advancing an entirely new healthcare paradigm.
Dr. Kapp received his B.S. in Biochemistry from the University of Georgia and his M.S. in Immunology and M.D. at the Medical College of Georgia, where he graduated with honors and was inducted into Alpha Omega Alpha, the medical honor society. He attended the Baylor College of Medicine in Houston, Texas for residency in Orthopaedic Surgery and completed his specialty training in 1994.
Dr. Kapp is a board-certified orthopaedic surgeon and a Fellow in the American Academy of Orthopaedic Surgeons, has served on the Board of Directors of the Missouri Orthopaedic Association and has been chair of the Legislative Affairs Committee. Until 2005, he served as flight surgeon in the US Air Force Reserves with the rank of Major.
Dr. Kapp is a dynamic entrepreneur who has founded several healthcare start-ups, ranging from surgical centers and hospitals to electronic health record systems and medical real estate developments.